↓ Skip to main content

Serenoa repens for benign prostatic hyperplasia

Overview of attention for article published in Cochrane database of systematic reviews, December 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Readers on

mendeley
71 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Serenoa repens for benign prostatic hyperplasia
Published in
Cochrane database of systematic reviews, December 2012
DOI 10.1002/14651858.cd001423.pub3
Pubmed ID
Authors

James Tacklind, Roderick MacDonald, Indy Rutks, Judith U Stanke, Timothy J Wilt

Abstract

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate, which can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto, or dwarf palm plant, Serenoa repens (SR), which is also known by its botanical name of Sabal serrulatum, is one of several phytotherapeutic agents available for the treatment of BPH.

Twitter Demographics

The data shown below were collected from the profiles of 17 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 71 100%

Demographic breakdown

Readers by professional status Count As %
Professor > Associate Professor 1 1%
Unknown 70 99%
Readers by discipline Count As %
Medicine and Dentistry 1 1%
Unknown 70 99%

Attention Score in Context

This research output has an Altmetric Attention Score of 51. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2019.
All research outputs
#293,255
of 12,477,106 outputs
Outputs from Cochrane database of systematic reviews
#747
of 8,708 outputs
Outputs of similar age
#5,271
of 257,853 outputs
Outputs of similar age from Cochrane database of systematic reviews
#47
of 427 outputs
Altmetric has tracked 12,477,106 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,708 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.8. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 257,853 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 427 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.